Search

Author/Creator Miwa, Hiroko

1. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period. Issue 1 (2nd January 2018)

Authors:
Ogata, Atsushi; Tanaka, Yoshiya; Ishii, Tomonori; Kaneko, Motohide; Miwa, Hiroko; Ohsawa, Shino
Journal:
Modern rheumatology
Issue:
Volume 28:Issue 1(2018)
Page Start:
76
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study. Issue 5 (3rd September 2019)

Authors:
Ogata, Atsushi; Tanaka, Yoshiya; Ishii, Tomonori; Kaneko, Motohide; Miwa, Hiroko; Ohsawa, Shino; Yamakawa, Reiji
Journal:
Modern rheumatology
Issue:
Volume 29:Issue 5(2019)
Page Start:
767
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Pd–PdO Nanodomains on Amorphous Ru Metallene Oxide for High‐Performance Multifunctional Electrocatalysis. Issue 12 (7th February 2023)

Authors:
Do, Viet‐Hung; Prabhu, P; Jose, Vishal; Yoshida, Takefumi; Zhou, Yingtang; Miwa, Hiroko; Kaneko, Takuma; Uruga, Tomoya; Iwasawa, Yasuhiro; Lee, Jong‐Min
Journal:
Advanced materials
Issue:
Volume 35:Issue 12(2023)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗